Return on Tangible Equity (Quarterly)

Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity

Arrowhead Pharmaceuticals, Inc. (ARWR) had Return on Tangible Equity of 54.38% for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$542.71M
Net Income	$370.44M
Cost of Goods Sold	--
Gross Profit	$542.71M
Operating Expenses	$161.51M
Operating Income	$381.20M
Non-Operating Income/Expense	$-11.59M
Pre-Tax Income	$369.62M
Normalized Pre-Tax Income	$369.62M
Income after Taxes	$367.86M
Income from Continuous Operations	$367.86M
Consolidated Net Income/Loss	$367.86M
Normalized Income after Taxes	$367.86M
EBIT	$381.20M
EBITDA	$390.20M
Weighted-Average Shares Outstanding (Basic)	133.36M
Weighted-Average Shares Outstanding (Diluted)	134.48M
Earnings per Share (EPS) (Basic)	$2.78
Earnings per Share (EPS) (Diluted)	$2.75
Balance Sheet Financials
Current Assets	$1.14B
Property, Plant, and Equipment	$384.80M
Long-Term Assets	$438.28M
Total Assets	$1.57B
Current Liabilities	$220.54M
Long-Term Debt	$208.93M
Long-Term Liabilities	$668.73M
Total Liabilities	$889.27M
Common Equity	$684.23M
Tangible Shareholders Equity	$676.51M
Shareholders Equity	$684.23M
Common Shares Outstanding	138.06M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$313.78M
Cash Flow from Investing Activities	$-343.30M
Cash Flow from Financial Activities	$113.02M
Beginning Cash	$102.69M
End Cash	$185.71M
Increase/Decrease in Cash	$83.02M
Stock-Based Compensation	$31.24M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.15
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.23
Debt to Equity Ratio	0.40
Gross Margin	100.00%
Operating Margin	70.24%
EBIT Margin	70.24%
EBITDA Margin	--
Pre-Tax Profit Margin	68.11%
Profit Margin	68.26%
Free Cash Flow	$300.97M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.34
Inventory Turnover	--
Receiveable Turnover	229.48
Days Sales in Receivables	0.39
Return on Equity	53.76%
Return on Tangible Equity	54.38%
Return on Assets	23.38%
Return on Investments	41.19%
Book Value Per Share	$4.96
Free Cash Flow per Share	$2.24
Operating Cash Flow per Share	$2.33

Data from Zacks Investment Research, Inc.